Navigation Links
Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
Date:3/28/2011

NUTLEY, N.J., March 28, 2011 /PRNewswire/ -- Roche announced today that Janet Hammond, MD, Ph.D., has joined the company as Vice President, Translational Medicine – Virology in Pharmaceutical Research and Early Development (pRED). In her new role, Janet will report to Jacques Banchereau, Ph.D., Discovery and Translational Area (DTA) Head for Inflammation and Virology, and Chief Scientific Officer at Nutley, and be responsible for driving strategy and implementation of early clinical development for the Virology DTA.

Prior to Roche, Janet served as Chief Medical Officer and Senior VP of Global Medical Affairs at Valeant Pharmaceuticals International where she was responsible for medical affairs and pharmacovigilence activities worldwide. As Chair of the Global Safety Board, Janet was also responsible for ensuring patient, clinical trial and product safety. Other industry positions include: Bristol-Myers Squibb, where as Group Director, Global Clinical Research, Virology and Infections Diseases, she was medical lead for the Early Clinical research team for HIV Early Development and Virology Life Cycle management; and GlaxoSmithKline, where she served as Head of Clinical Drug Discovery Virology, responsible for developing a new department as well as medical strategy, IND submissions and clinical development of small molecules and vaccines.

"Janet's background and experience will be a great addition to our efforts to drive Translational Medicine as well as Virology within Roche as we continue our quest to find new and more effective approaches to drug development, ultimately providing better options for patients," said Jacques Banchereau.

"I am delighted to be joining Roche. The company is on the cutting edge of research in the areas of virology and translational medicine, and I am very excited to be able to be part of an impressive team of people who are striving to develop new approaches for the treatment of patients with infectious diseases," said Hammond.

With an impressive 13-year career in the pharmaceutical industry, and a broad academic background in several medical areas, Janet has made numerous contributions to the field. These include: three New Drug Applications (NDA) and Marketing Authorization Application (MAA) submissions, more than 10 supplemental NDAs, and project lead in translational medicine on more than 10 Investigational New Drug (IND) submissions. In addition, she has been involved in launch preparations for three new drugs, and managed the integration and development of new departments as a result of major company acquisitions.

Janet received her MD and Ph.D. degrees from the University of Cape Town, South Africa and an ScM in Clinical Investigation from Johns Hopkins University. Currently, she is an adjunct faculty member at UCLA and attending physician at the West Los Angeles Veterans Administration Hospital.

She is also a member of the College of Medicine of South Africa, International Society of Infectious Diseases, Infectious Diseases Society of America and Southern African Critical Care Society. Janet, a reviewer for Lancet and the European Journal of Medical Microbiology, has authored more than 45 publications and is a sought after presenter at scientific meetings. In addition, Janet has received numerous awards and honors during her career.

Janet is married to Peter Potgieter MD, Ph.D. and will be relocating to Nutley from southern California.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael Porter, Janet Woodcock, Peter Senge Among Speakers at Inaugural Innovation in Healthcare Symposium
2. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
3. Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance
4. Veteran Executive Ron Wall Joins Advanstar Communications as Executive Vice President, Pharmaceutical/Science
5. Former PayPal, Palantir Executive Jason Portnoy Joins Practice Fusion as CFO
6. Medical Devices and Diagnostics Analyst Joins MLV to Further Expand its Coverage of the Life Sciences Sector
7. Ultrasound Industry Expert, Chris Daft, Joins Samplify Systems
8. Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience
9. Josephine Martin Joins PhRMA as Exec VP of Public Affairs
10. Elka Nir Joins VisionCare Board of Directors
11. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... ... why retirement is not an option to senior, upper-level executives speaking at a ... , "A senior, high-level executive is an asset to be fully realized ...
(Date:9/25/2017)... ... September 25, 2017 , ... Leonard Bley, MD ... generation for LASIK in Manhattan with Contoura Vision, the latest WaveLight® topographic-guided laser ... available in the United States to correct nearsightedness and nearsightedness with astigmatism. This ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Earlypicker is ... for a one-stop shop for the hottest Korean cosmetics and fashion trends sweeping the ... a company that’s already well-known for the great offerings that allow Koreans everywhere to ...
(Date:9/25/2017)... ... 2017 , ... Dr. Edward Hebert is celebrating his 33rd anniversary ... else,” said Dr. Hebert. “I count my blessings daily for the opportunity that the ... is what I look forward to the most. The relationships I have with my ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often ... Deborah Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s ... invited us to come over before the baby had to go back to her ...
Breaking Medicine News(10 mins):